Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome (NCT06437210) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
Colombia200 participantsStarted 2022-02-15
Plain-language summary
Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset. Prolonged COVID is characterized on the basis of symptoms such as fatigue, headache, dyspnea, and anosmia present for weeks, with older age, high body mass index, and female sex being more susceptible.
Accordingly, and in the absence of specific treatments, the present study seeks to establish a treatment protocol for Post-COVID syndrome through the application of the dietary supplement VIUSID, due to its anti-inflammatory and immunomodulatory effect, thus helping to reduce and/or control the symptoms of the syndrome.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patients with one or more of the following symptoms, persistent after suffering COVID-19:
* Extreme tiredness (Fatigue).
* Shortness of breath
* Chest pain
* Problems with memory or concentration ("Brain fog")
* Insomnia
* Palpitations
* Dizziness
* Tingling
* Joint pain
* Depression and anxiety
* Tinnitus or ear pain
* Malaise, diarrhea, stomach pain, loss of appetite
* Fever, cough, headache, dry throat, changes in sense of smell or taste
* Rash
Exclusion Criteria:
* Patients with a positive diagnosis of COVID-19 in the last 14 days.
* Patients who have presented symptoms similar to Post-COVID syndrome prior to the onset of COVID-19 due to a concomitant disease.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evaluation of the symptoms associated with post-COVID-19 syndrome.
Timeframe: 30 days
2
Evaluation of inflammation associated with Post-COVID-19 syndrome.
Timeframe: 30 days
3
Evaluation of oxidative stress associated with Post-COVID-19 syndrome
Timeframe: 30 days
4
Evaluation of pulmonar fibrosis associated with Post-COVID-19 syndrome